parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (36 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	4 Parkinson's papers of 403	0.79
pathways Reactome	8 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 10481

EHMT2 in dopamine neurons, braak+0.12 (p 0.749) → -0.27 (p 0.485)receipt 10488
EHMT2 in oligodendrocytes, braak-0.56 (p 0.115) → -0.24 (p 0.530)receipt 10487

receipt 10488: EHMT2 in dopamine neurons, braak

power: full sample +0.13 (p 0.609, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.11 (p 0.652, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.728, n 18). could be the mix.
skeptic: leave-one-out range +0.01 to +0.26, sign flips 0; without severely affected donors +0.13 (p 0.609, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EHMT2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10487: EHMT2 in oligodendrocytes, braak

power: full sample -0.34 (p 0.167, n 18), 95% CI -0.70 to +0.15. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.31 (p 0.207, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.35 (p 0.153, n 18). could be the mix.
skeptic: leave-one-out range -0.52 to -0.24, sign flips 0; without severely affected donors -0.34 (p 0.167, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EHMT2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts